Cargando…

Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis

BACKGROUND: Immune checkpoint inhibitors and targeted therapies are approved for adjuvant treatment of patients with resected melanoma; however, they have not been compared in randomized controlled trials (RCTs). We compared the efficacy and safety of adjuvant nivolumab with other approved treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toor, Kabirraaj, Middleton, Mark R., Chan, Keith, Amadi, Adenike, Moshyk, Andriy, Kotapati, Srividya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784366/ https://www.ncbi.nlm.nih.gov/pubmed/33402121 http://dx.doi.org/10.1186/s12885-020-07538-1

Ejemplares similares

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma
por: Samlowski, Wolfram, et al.
Publicado: (2022)

Cost–Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France
por: Bregman, Bruno, et al.
Publicado: (2020)

Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection
por: Batteson, Rachael, et al.
Publicado: (2019)

Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067
por: Baker, Timothy, et al.
Publicado: (2022)

Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma
por: Federico Paly, Victoria, et al.
Publicado: (2022)

A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma(☆)
por: Tarhini, A.A., et al.
Publicado: (2021)

Societal preferences for adjuvant melanoma health states: UK and Australia
por: Middleton, Mark R., et al.
Publicado: (2017)

Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data
por: Freeman, Morganna, et al.
Publicado: (2019)

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
por: Weber, Jeffrey S., et al.
Publicado: (2023)

Retrospective analysis of drug utilization, health care resource use, and costs associated with IFN therapy for adjuvant treatment of malignant melanoma
por: Zhang, Ying, et al.
Publicado: (2015)

Neoadjuvant relatlimab and nivolumab in resectable melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2022)

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
por: Larkin, James, et al.
Publicado: (2023)

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
por: Dalle, Stéphane, et al.
Publicado: (2021)

Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma
por: Khushalani, Nikhil I, et al.
Publicado: (2022)

Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2023)

Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
por: Lee, D., et al.
Publicado: (2018)

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
por: Mandalá, Mario, et al.
Publicado: (2021)

Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
por: Lee, D., et al.
Publicado: (2018)

Safety and efficacy of nivolumab compared with other regimens in patients with melanoma: A network meta-analysis
por: Almohideb, Mohammad
Publicado: (2022)

Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival
por: Weber, Jeffrey S., et al.
Publicado: (2022)

An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA
por: Bensimon, Arielle G., et al.
Publicado: (2020)

Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival
por: Weber, Jeffrey S., et al.
Publicado: (2022)

Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study
por: Yokota, Kenji, et al.
Publicado: (2019)

Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma: A Meta-Analysis
por: Serritella, Anthony V., et al.
Publicado: (2023)

Nivolumab exposure–response analysis for adjuvant treatment of melanoma supporting a change in posology
por: Sanghavi, Kinjal, et al.
Publicado: (2021)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
por: Kirkwood, John M., et al.
Publicado: (2023)

Adjuvant interferon in the treatment of melanoma
por: Middleton, M R
Publicado: (1999)

Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial
por: Schwarze, Julia Katharina, et al.
Publicado: (2022)

Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck
por: Hanna, Glenn J., et al.
Publicado: (2022)

Subset analysis of the safety and efficacy of nivolumab in elderly patients with metastatic melanoma
por: Freeman, Morganna, et al.
Publicado: (2015)

Adjuvant interferon in the treatment of melanoma – reply
por: Middleton, M R
Publicado: (2000)

Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany
por: Wahler, S, et al.
Publicado: (2020)

Real-World Effectiveness, Safety, and Health-Related Quality of Life in Patients Receiving Adjuvant Nivolumab for Melanoma in Belgium and Luxembourg: Results of PRESERV MEL †
por: Rogiers, Anne, et al.
Publicado: (2023)

Adjuvant interferon in melanoma – a resurrection?
por: Middleton, M R, et al.
Publicado: (2001)

Incorporating alternative design clinical trials in network meta-analyses
por: Thorlund, Kristian, et al.
Publicado: (2014)

Successful Treatment of Unresectable Advanced Melanoma by Administration of Nivolumab With Ipilimumab Before Primary Tumor Resection
por: Fujimura, Taku, et al.
Publicado: (2019)

Real‐world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study
por: Middleton, Mark R., et al.
Publicado: (2016)

Cost‐effectiveness of ipilimumab versus high‐dose interferon as an adjuvant therapy in resected high‐risk melanoma
por: Salans, Mia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9gndobm2k0592k7k0bcum1h4dr